✦ LIBER ✦

The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib

✍ Scribed by Qiang Nie; Zhen Wang; Guo-chun Zhang; She-juan An; Jia-yin Lin; Ai-lin Guo; Rong Li; Bin Gan; Ying Huang; Tony S. Mok; Yi-long Wu

Book ID: 113586962
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 255 KB
Volume: 570
Category: Article
ISSN: 0014-2999
DOI: 10.1016/j.ejphar.2007.05.015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CYP1A1*2A polymorphism as a predictor of

CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism

✍ Qiang Nie; Xue-ning Yang; She-juan An; Xu-chao Zhang; Jin-ji Yang; Wen-zhao Zhon 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 289 KB

Gefitinib as First-line Treatment in Eld

Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Lung Adenocarcinoma: Results of a Nagano Lung Cancer Research Group Study

✍ Kazuhiro Asami; Tomonobu Koizumi; Kazuya Hirai; Shingo Ameshima; Akihiro Tsukada 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 308 KB

Epidermal growth factor receptor intron

Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6

✍ Sae-Won Han; Do-Youn Oh; Seock-Ah Im; Sook Ryun Park; Keun-Wook Lee; Hong Suk So 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB

PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (

PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

✍ G. de Lima Lopes 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

P-484 Synchronous overexpression of epid

P-484 Synchronous overexpression of epidermal growth factor receptor and HER2-NEU is a predictor of poor outcome in patients with stage I non-small cell lung cancer

✍ Onn, Amir; Correa, Arlene M.; Gilcrease, Michael; Massarelli, Erminia; Bucana, C 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 172 KB

Prospective Study of Gefitinib in Epider

Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization-Positive/Phospho-Akt-Positive or Never Smoker Patients With Advanced Non-Small-Cell Lung Cancer: The ONCOBELL Trial

✍ Cappuzzo, F.; Ligorio, C.; Janne, P. A.; Toschi, L.; Rossi, E.; Trisolini, R.; P 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 130 KB